Donna is the CEO of Xora Innovation, an early-stage deep tech investing platform of Temasek. With over 20 years of experience in science commercialization, venture creation, and venture capital investing, Donna brings to bear significant expertise in the nuanced process of transforming scientific innovation into commercially viable ventures.
Previously, she served in founding executive roles, as Chief Business Officer of TARA Biosystems, enabling the development of precision cardio-medicines, and as a co-founder of Vixen Pharmaceuticals, a company dedicated to therapies for autoimmune dermatologic conditions, acquired by Aclaris Therapeutics (NASDAQ: ACRS), and as Chief Business Officer of Allied-Bristol Life Sciences, a joint venture between Bristol-Myers Squibb (NYSE: BMS) and Allied Minds, pursuing the development of discovery stage assets for heart failure, oncology, immune disorders, and fibrosis.
Donna was also Vice President, Investments at Allied Minds, a publicly-traded (LSE: ALM) venture creation platform for U.S. university and federal lab innovations in the communications, semiconductor, and cybersecurity domains, and was Director at Columbia Technology Ventures, where she oversaw technology development and monetization of IP arising from the engineering and basic science labs at Columbia University.
Donna received her MBA and MPH from Columbia University and holds a BA in the Natural Sciences from The Johns Hopkins University.